Valuation: Cogent Biosciences, Inc.

Market Cap 5.12B 4.57B 4.24B 3.85B 7.23B 486B 7.34B 50.79B 19.95B 254B 19.23B 18.82B 812B P/E 2026 *
-13.1x
P/E 2027 * -26.8x
Enterprise Value 4.99B 4.45B 4.13B 3.75B 7.04B 474B 7.16B 49.5B 19.44B 248B 18.74B 18.34B 792B EV / Sales 2026 *
834x
EV / Sales 2027 * 17.5x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.66%
1 week-3.19%
Current month-6.28%
1 month-4.73%
3 months-23.21%
6 months-19.44%
Current year-15.51%
1 week 27.74
Extreme 27.735
30.23
1 month 27.74
Extreme 27.735
32.85
Current year 27.74
Extreme 27.735
43.39
1 year 13.78
Extreme 13.78
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 23/10/2020
Director of Finance/CFO 45 01/06/2018
Chief Tech/Sci/R&D Officer 52 06/04/2021
Director TitleAgeSince
Director/Board Member 68 01/02/2018
Director/Board Member 74 26/07/2019
Director/Board Member 59 26/07/2019
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Free

Director

759 0.0004%
27/8/26 Exercice

Director

136,530 0.0787%
1/7/26 Free

Director

627 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.66%-3.19%+83.10%+230.87% 5.12B
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+7.17%+10.77%+77.89% 51.2B
+0.30%+0.19%+2.53%+56.14% 51.19B
-0.38%+2.31%+29.98%+40.71% 43.93B
+0.30%+4.43%+16.99%+120.94% 41.96B
+2.35%-4.01%+236.69%+497.21% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+3.97%+21.34%+22.33% 22.5B
Average +1.01%-0.35%+50.91%+117.50% 37.75B
Weighted average by Cap. +0.98%-0.03%+46.53%+108.05%

Financials

2026 *2027 *
Net sales 5.99M 5.34M 4.95M 4.5M 8.45M 568M 8.58M 59.36M 23.31M 297M 22.47M 22M 949M 284M 253M 235M 213M 400M 26.93B 406M 2.81B 1.1B 14.06B 1.06B 1.04B 44.98B
Net income -399M -356M -330M -300M -563M -37.87B -572M -3.95B -1.55B -19.78B -1.5B -1.47B -63.25B -213M -190M -176M -160M -300M -20.21B -305M -2.11B -829M -10.55B -799M -782M -33.76B
Net Debt -130M -116M -107M -97.44M -183M -12.31B -186M -1.29B -505M -6.43B -486M -476M -20.55B -158M -141M -131M -119M -223M -15B -227M -1.57B -615M -7.84B -593M -581M -25.06B
Projected Income Statement - Annual - Cogent Biosciences, Inc.
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
19/10/26 USD 30.01 +1.66% 2,438,411
16/10/26 USD 29.52 +0.03% 2,783,048
15/10/26 USD 29.51 +4.83% 3,039,765
14/10/26 USD 28.15 +0.21% 2,295,507
13/10/26 USD 28.09 -5.67% 2,995,450
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Cogent Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
30.01USD
Average target price
55.82USD
Spread / Average Target
+86.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cogent Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. COGT Stock